Development of a microcosting protocol to determine the economic cost of diagnostic genomic testing for rare diseases in Australia

IntroductionGenomic testing is a relatively new, disruptive and complex health technology with multiple clinical applications in rare disease, cancer and infection control. Genomic testing is increasingly being implemented into clinical practice, following regulatory approval, funding and adoption in models of care, particularly in the area of rare disease diagnosis. A... Show more